Skip to main content

Table 1 Patient characteristics in the two-drug (palonosetron+DEX) and three-drug (NK1RA + palonosetron+DEX) groups before and after a propensity score-matching

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

  Two-drug before matching Three-drug before matching p value Two-drug after matching Three-drug after matching p value
Case number 97 215   97 97  
Age (mean ± SD) 66.4 ± 9.9 63.2 ± 11.2 0.011 66.4 ± 9.9 64.7 ± 9.5 0.49
Sex (M/F), n (%) 45/52 103/112 0.80 45/52 37/60 0.24
(46.4/53.6) (47.9/52.1) (46.4/53.6) (38.1/61.9)
ECOG PS0/1,2, n (%) 54/43 96/119 0.07 54/43 51/46 0.67
(55.7/44.3) (44.7/55.3) (55.7/44.3) (51.5/48.5)
Primary organ, n (%) Colon/Ovary+Uterus/Lung/Stomach 56/16/14/11 155/37/9/14 0.003 56/16/14/11 57/24/7/9 0.24
(57.7/16.5/14.4/11.3) (72.1/17.2/4.2/6.5) (57.7/16.5/14.4/11.3) (58.8/24.7/7.2/9.3)
Type of anticancer drugs, n (%) L-OHP/CBDCA/CPT-11 46/28/23 132/46/37 0.07 46/28/23 52/31/14 0.26
(47.4/28.9/23.7) (61.4/21.4/17.2) (47.4/28.9/23.7) (53.6/33.0/14.4)
Sequence of chemotherapy, n (%) 1st course/2nd-3rd courses 39/58 88/127 0.90 39/58 45/52 0.38
(40.2/59.8) (40.9/59.1) (40.2/59.8) (46.4/53.6)
Additional oral DEX on day 2–3 of chemotherapy, n (%) 9 (9.3) 30 (14.0) 0.25 9 (9.3) 12 (12.4) 0.49
  1. NK1RA neurokinin 1 receptor antagonist, DEX dexamethasone, M male, F female, PS performance status, L-OHP oxaliplatin, CBDCA carboplatin, CPT-11 irinotecan, SD standard deviation